Amylin-Incretin Combination Therapy
Pairing amylin-pathway agonists with incretin agonists adds a complementary satiety mechanism that raises weight loss beyond incretin monotherapy ceilings.
Developed mainly in: Switzerland, Denmark and United StatesImpacting: North America, Europe and Rest of Asia
Eli Lilly reported Phase 2b results at the EASD meeting in Milan for EloraTZP, pairing the amylin agonist eloralintide with tirzepatide. Across 367 adults with obesity or overweight plus type 2 diabetes, the combination produced up to 23.3% average weight loss at 48 weeks versus 14.8% for tirzepatide alone and 3% for placebo, with added A1C reduction. Phase 3 begins this year.
This is one of 24 signals scored in our latest scan.
Track Them Free For 14 Days →Since we flagged this
First flagged
9 June 2026 · score 8.0/10
Corroborating sources since flagging
34
Latest signals
Tracked from 3 signals, each traced to its source.
- Triple-mechanism obesity combination delivers 23% weight loss in mid-stage diabetes trial
Biospace · 6 Oct 2026
- Amylin-GLP-1 combination beats tirzepatide on weight loss in phase 3 head-to-head
Newswire · 2 Oct 2026
- [Ad hoc announcement pursuant to Art. 53 LR] Roche
Globenewswire · 9 Jun 2026
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Biotech
Other innovations the engine is currently tracking in this industry.
- Virtual Trial Outcome Prediction7.0/ 10 · 2 signals
- Multi-Receptor Incretin Co-Agonists6.8/ 10 · 5 signals
- Programmable RNA And Expression Control7.7/ 10 · 3 signals
- Multivalent Seasonal Respiratory mRNA Vaccines6.5/ 10 · 2 signals
- Novel Food Approval Pathways For Cultivated Meat6.9/ 10 · 7 signals
- Clinical Genome-Editing Therapeutics7.8/ 10 · 6 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.